MOST indexes | All participants | PRR-ROC | PPS-ROC ≥3 | P value* n1 vs n2 | |||
N0 | Symptomatic at baseline, n0 (%) | N1 | Symptomatic at baseline, n1 (%) | N2 | Symptomatic at baseline, n2 (%) | ||
MOST-Abdo† | 893 | 481 (54) | 535 | 296 (55) | 358 | 185 (52) | 0.28 |
MOST-Psych‡ | 896 | 472 (53) | 534 | 278 (52) | 362 | 194 (54) | 0.65 |
MOST-DorT§ | 903 | 314 (35) | 540 | 192 (36) | 363 | 122 (34) | 0.55 |
MOST-Chemo¶ | 898 | 244 (27) | 537 | 155 (29) | 361 | 89 (25) | 0.16 |
MOST-Well-being** | 883 | 633 (72) | 527 | 377 (72) | 356 | 256 (72) | 0.90 |
N0 | Symptom improvement, n0 (%) | N1 | Symptom improvement, n1 (%) | N2 | Symptom improvement, n2 (%) | P value* n1 vs n2 | |
MOST-Abdo | 481 | 190 (40) | 296 | 107 (36) | 185 | 83 (45) | 0.06 |
MOST-Psych | 472 | 165 (35) | 278 | 93 (33) | 194 | 72 (37) | 0.41 |
MOST-DorT | 314 | 118 (38) | 192 | 66 (34) | 122 | 52 (43) | 0.14 |
MOST-Chemo | 244 | 68 (28) | 155 | 50 (32) | 89 | 18 (20) | 0.04 |
MOST-Well-being | 633 | 156 (25) | 377 | 85 (23) | 256 | 71 (28) | 0.14 |
N0 | Time to improvement, median (IQR) weeks | N1 | Time to improvement, median (IQR) weeks | N2 | Time to improvement, median (IQR) weeks | P value†† | |
MOST-Abdo | 190 | 5 (4–9) | 107 | 4 (4–9) | 83 | 6 (4–12) | 0.04 |
MOST-Psych | 165 | 4 (4–8) | 93 | 4 (4–6) | 72 | 5 (4–14) | 0.26 |
MOST-DorT | 118 | 5 (4–9) | 66 | 5 (4–8) | 52 | 5 (4–10) | 0.57 |
MOST-Chemo | 68 | 5 (4–13) | 50 | 5 (4–13) | 18 | 7 (4–13) | 0.54 |
MOST-Well-being | 156 | 6 (4–12) | 85 | 5 (4–11) | 71 | 6 (4–16) | 0.15 |
*χ2 test.
†MOST-Abdo, 2 symptoms: abdominal pain, discomfort and/or cramps; abdominal swelling, bloating and/or fullness.
‡MOST-Psych, 2 symptoms: anxiety (feeling worried); depression (feeling sad).
§MOST-DorT, 11 symptoms: fatigue (tiredness); trouble eating; indigestion; nausea; vomiting; diarrhea; constipation; shortness of breath; difficulty swallowing; trouble sleeping; bladder problems.
¶MOST-Chemo, 6 symptoms: altered sense of taste; sore mouth or throat; hair loss; skin rash; numbness or pins and needles; sore hands and feet.
**MOST-Well-being, 3 items: physical well-being, emotional well-being, overall well-being.
††Wilcoxon rank-sum test.
IQR, interquartile range; MOST, Measure of Ovarian Cancer Symptoms and Treatment; n, number; N, denominator; PPS-ROC ≥3, potentially platinum sensitive recurrent ovarian cancer after ≥3 lines of chemotherapy; PRR-ROC, platinum resistant/refractory recurrent ovarian cancer.